Tight Glycemic Control: Critical Care’s Balancing Act
Over a decade ago, the New England Journal of Medicine published a study identifying tight glycemic control in the intensive care unit as a critical step to improving patient outcomes. Today, a small pack of companies is trying to finally deliver on the promise.
You may also be interested in...
Research Briefs: HeartWare Adds Patients To ENDURANCE; GlySure ICU Glucose Trial; Biotronik Home Monitoring
FDA has approved HeartWare’s plan to add more patients to the ENDURANCE trial of its HVAD ventricular assist device as a destination therapy for patients with end-stage heart failure. Results of a pilot trial of GlySure’s continuous glucose monitoring system were presented at a conference in South Africa. More research.
FDA is encouraging industry to submit study designs for newer, more accurate continuous glucose monitors for hospital use. It gathered experts at a June 25 public meeting to discuss questions around indications for use and trial designs.
Is innovation in the diabetes device market being hampered by a slowdown in FDA approvals? That question was the unofficial, under-riding theme at the American Diabetes Association 71st Scientific Sessions in June.